Identifying Complex High-Risk Individuals (HRI-C) for Early Detection of Occult Pancreatic Cancers Using Risk Models and Biomarkers. DOI Creative Commons
Randall E. Brand, David C. Whitcomb,

Bechien Wu

и другие.

SMART-MD journal of precision medicine., Год журнала: 2024, Номер 1(3), С. e66 - e78

Опубликована: Дек. 23, 2024

Early detection and diagnosis of pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) offers the best option for effective treatment prolonged survival. Image-based screening programs are useful in early cancers high-risk individuals (HRI) defined by strong family history and/or pathogenic variants (PV) hereditary syndrome (HCS) genes associated with an increased risk PDAC development. However, this only applies about 10% people who eventually develop cancer. An additional 15% PDACs a cystic neoplasms. Thus, majority (~75%) patients diagnosed not candidates surveillance under existing framework. Based on growing evidence we believe that is also possible what call Complex High-Risk Individuals (HRI-C) through frequent, time-limited image-based screening. These HRI-C identified combining multiple clinical genetic factors alongside markers (e.g. history, past medical social worrisome individual or combinations biomarkers occult older (>50 years) such as new onset diabetes (NOD), idiopathic acute chronic pancreatitis, maldigestion exocrine insufficiency (EPI), abnormal liver injury test (especially biliary), unexplained weight loss typical cancer-associated pain patterns). Here propose potentially cost-effective decision pathway aimed at improving detection, outcomes large group developing PDAC.

Язык: Английский

MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications DOI Open Access
Roland Madadjim,

Thuy An,

Juan Cui

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(7), С. 3914 - 3914

Опубликована: Март 31, 2024

Pancreatic cancer remains a formidable malignancy characterized by high mortality rates, primarily attributable to late-stage diagnosis and dearth of effective therapeutic interventions. The identification reliable biomarkers holds paramount importance in enhancing early detection, prognostic evaluation, targeted treatment modalities. Small non-coding RNAs, particularly microRNAs, have emerged as promising candidates for pancreatic recent years. In this review, we delve into the evolving role cellular circulating miRNAs, including exosomal diagnosis, prognosis, targeting cancer. Drawing upon latest research advancements omics data-driven biomarker discovery, also perform case study using public datasets address commonly identified discrepancies, challenges, limitations. Lastly, discuss analytical approaches that integrate multimodal analyses incorporating clinical molecular features, presenting new insights identifying robust miRNA-centric biomarkers.

Язык: Английский

Процитировано

12
Biomarkers, Omics and Artificial Intelligence for Early Detection of Pancreatic Cancer. DOI Creative Commons
Kate Murray, Lucy Oldfield, Irena Stefanova

и другие.

Seminars in Cancer Biology, Год журнала: 2025, Номер 111, С. 76 - 88

Опубликована: Фев. 20, 2025

Язык: Английский

Процитировано

1
Identifying Complex High-Risk Individuals (HRI-C) for Early Detection of Occult Pancreatic Cancers Using Risk Models and Biomarkers. DOI Creative Commons
Randall E. Brand, David C. Whitcomb,

Bechien Wu

и другие.

SMART-MD journal of precision medicine., Год журнала: 2024, Номер 1(3), С. e66 - e78

Опубликована: Дек. 23, 2024

Early detection and diagnosis of pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) offers the best option for effective treatment prolonged survival. Image-based screening programs are useful in early cancers high-risk individuals (HRI) defined by strong family history and/or pathogenic variants (PV) hereditary syndrome (HCS) genes associated with an increased risk PDAC development. However, this only applies about 10% people who eventually develop cancer. An additional 15% PDACs a cystic neoplasms. Thus, majority (~75%) patients diagnosed not candidates surveillance under existing framework. Based on growing evidence we believe that is also possible what call Complex High-Risk Individuals (HRI-C) through frequent, time-limited image-based screening. These HRI-C identified combining multiple clinical genetic factors alongside markers (e.g. history, past medical social worrisome individual or combinations biomarkers occult older (>50 years) such as new onset diabetes (NOD), idiopathic acute chronic pancreatitis, maldigestion exocrine insufficiency (EPI), abnormal liver injury test (especially biliary), unexplained weight loss typical cancer-associated pain patterns). Here propose potentially cost-effective decision pathway aimed at improving detection, outcomes large group developing PDAC.

Язык: Английский

Процитировано

0